Catalyst Pharmaceuticals, Inc.
CPRX
$21.12
-$0.21-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 534.65M | 491.73M | 460.48M | 434.48M | 411.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 534.65M | 491.73M | 460.48M | 434.48M | 411.35M |
| Cost of Revenue | 88.19M | 81.49M | 73.83M | 149.10M | 146.71M |
| Gross Profit | 446.46M | 410.24M | 386.65M | 285.37M | 264.64M |
| SG&A Expenses | 177.71M | 177.74M | 175.58M | 163.26M | 150.93M |
| Depreciation & Amortization | 37.38M | 37.38M | 37.09M | 36.23M | 35.38M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 303.28M | 296.61M | 286.51M | 348.60M | 333.02M |
| Operating Income | 231.37M | 195.12M | 173.97M | 85.88M | 78.33M |
| Income Before Tax | 258.46M | 216.26M | 188.79M | 93.56M | 86.29M |
| Income Tax Expenses | 61.11M | 52.37M | 45.99M | 25.41M | 21.17M |
| Earnings from Continuing Operations | 197.35 | 163.89 | 142.80 | 68.15 | 65.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 197.35M | 163.89M | 142.80M | 68.15M | 65.12M |
| EBIT | 231.37M | 195.12M | 173.97M | 85.88M | 78.33M |
| EBITDA | 269.17M | 232.90M | 211.43M | 122.45M | 114.04M |
| EPS Basic | 1.65 | 1.38 | 1.24 | 0.58 | 0.59 |
| Normalized Basic EPS | 1.30 | 1.11 | 1.01 | 0.50 | 0.48 |
| EPS Diluted | 1.57 | 1.31 | 1.18 | 0.54 | 0.54 |
| Normalized Diluted EPS | 1.24 | 1.05 | 0.96 | 0.46 | 0.44 |
| Average Basic Shares Outstanding | 478.48M | 473.81M | 460.63M | 448.27M | 436.35M |
| Average Diluted Shares Outstanding | 503.30M | 499.75M | 487.22M | 468.38M | 457.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |